Stock DNA
Pharmaceuticals & Biotechnology
INR 26,022 Cr ()
107.00
37
0.10%
0.00
0.00%
20.02
Total Returns (Price + Dividend) 
Rubicon Research for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Earnings Conference Call
07-Aug-2026 | Source : BSEEarnings Conference Call
Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2026
07-Aug-2026 | Source : BSERubicon Research Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve The Un-Audited Standalone and Consolidated financial results of the Company for the quarter ended June 30 2026.
Announcement under Regulation 30 (LODR)-Newspaper Publication
04-Aug-2026 | Source : BSENewspaper Advertisment titled Notice of the 27th Annual General Meeting and voting Information
Corporate Actions 
No Upcoming Board Meetings
Rubicon Research Ltd has declared 150% dividend, ex-date: 07 Aug 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 14 Schemes (7.23%)
Held by 39 FIIs (7.52%)
General Atlantic Singapore Rr Pte Ltd (35.83%)
Shivanand Shankar Mankekar Huf (13.52%)
3.46%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is 29.22% vs -10.33% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is 88.33% vs -18.84% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 36.57% vs 50.40% in Mar 2025
YoY Growth in year ended Mar 2026 is 83.64% vs 47.63% in Mar 2025